14/04/2025 – AB Science today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with its lead compound masitinib, based on preclinical data Download PDF Post navigationPreviousPrevious post:Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschNextNext post:European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaRelated PostsAB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025Annual financial results as of 31 December, 2024May 12, 2025AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025
